Skip to main content

Clinical Trials Using Temozolomide

Review the clinical trials studying temozolomide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 88

Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Status: Active
Location: 441 locations
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Status: Active
Location: 386 locations
Dinutuximab with Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children with Newly Diagnosed High Risk Neuroblastoma
Status: Active
Location: 147 locations
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Status: Active
Location: 30 locations
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Status: Active
Location: 27 locations
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Status: Active
Location: 20 locations
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Status: Active
Location: 19 locations
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Status: Active
Location: 20 locations
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Status: Active
Location: 19 locations
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Status: Active
Location: 16 locations
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Status: Active
Location: 12 locations
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Status: Active
Location: 11 locations
Pembrolizumab, Olaparib, and Temozolomide for the Treatment of Recurrent Glioma
Status: Active
Location: 10 locations
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Status: Active
Location: 10 locations
BGB-290 and Temozolomide in Treating Adolescents and Young Adults with IDH1/2-Mutant Newly Diagnosed or Recurrent Grade I-IV Gliomas
Status: Active
Location: 19 locations
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
Status: Active
Location: 9 locations
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Status: Active
Location: 8 locations
Glucarpidase in Treating Patients with Central Nervous System B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 8 locations
Antiretrovirals and Laser Interstitial Thermal Therapy for the Treatment of Newly Diagnosed Unresectable High-Grade Gliomas, STARLITE Trial
Status: Active
Location: 7 locations
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Status: Active
Location: 12 locations
Abemaciclib, DNA-PK/TOR Kinase Inhibitor CC-115, Neratinib, or QBS10072S in Treating Patients with Brain Tumors after Biomarker Screening
Status: Active
Location: 6 locations
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
Status: Active
Location: 6 locations
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Status: Active
Location: 13 locations
Pembrolizumab, Olaparib and Temozolomide for the Treatment of Recurrent Glioblastoma
Status: Active
Location: 5 locations
Atezolizumab in Combination with Chemotherapy in Treating Pediatric Patients with Relapsed or Refractory Solid Tumors, VITAS Trial
Status: Active
Location: 5 locations